CDK2/Cyclin-E1 bound to CDK-Inhibitor Dinaciclib

sketchfab

The drug Dinaciclib is a Cyclin Dependent Kinase inhibitor that interacts with the Hinge loop and the active site of proteins in the CDK family such as CDK2. Dinaciclib is a broad-spectrum CDK inhibitor that has shown some promise in the treatment of tumours in humans. Due to the nature of the Hinge sequence, Dinaciclib has great specificity for members of the CDK family. The model above shows some of the key interactions of Dinaciclib with CDK2 to demonstrate this specificity. These include the key residues within the Hinge loop that undergo hydrogen bonding to the ligand, the location of the G-loop whose conformational change allows tighter binding, and the residues that contribute to Dinaciclib’s specificity for the CDK family of proteins and lackthereof for other kinases. PDB: 5L2W DOI: 10.1158/1535-7163.MCT-16-0300